drugset / Trial / NCT00279214
Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study will evaluate the vasopressor requirement, hemodynamic response and measures of tissue perfusion in patients with septic shock receiving an infusion of drotrecogin alfa (activated) compared to patients not receiving drotrecogin alfa (activated).
Timeline
- Start
- 2005-11
- Primary completion
- —
- Completion
- 2007-11
Outcome
Missed primary endpoint
registry analysis (superiority or other test); Drotrecogin Cohort vs Control Cohort; p = 0.238; Repeated Measures - propensity adjusted NCT00279214 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Drotrecogin alfa (activated) | Protein / enzyme biologic | — | Other |